These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

686 related items for PubMed ID: 17850361

  • 21. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
    Thompson IM, Pauler Ankerst D, Chi C, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA.
    J Clin Oncol; 2007 Jul 20; 25(21):3076-81. PubMed ID: 17634486
    [Abstract] [Full Text] [Related]

  • 22. [Results of transrectal focused ultrasound for the treatment of localized prostate cancer (120 patients with PSA < or + 10ng/ml].
    Poissonnier L, Gelet A, Chapelon JY, Bouvier R, Rouviere O, Pangaud C, Lyonnet D, Dubernard JM.
    Prog Urol; 2003 Feb 20; 13(1):60-72. PubMed ID: 12703356
    [Abstract] [Full Text] [Related]

  • 23. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
    Krakowsky Y, Loblaw A, Klotz L.
    J Urol; 2010 Jul 20; 184(1):131-5. PubMed ID: 20478589
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Do all patients with high-grade prostatic intraepithelial neoplasia on initial prostatic biopsy eventually progress to clinical prostate cancer?
    Izawa JI, Lega I, Downey D, Chin JL, Luke PP.
    BJU Int; 2005 Aug 20; 96(3):320-3. PubMed ID: 16042722
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Prostate cancer. Mortality and morbidity after non-curative treatment with aspects on diagnosis and treatment.
    Aus G.
    Scand J Urol Nephrol Suppl; 1994 Aug 20; 167():1-41. PubMed ID: 7542397
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance.
    Al Otaibi M, Ross P, Fahmy N, Jeyaganth S, Trottier H, Sircar K, Bégin LR, Souhami L, Kassouf W, Aprikian A, Tanguay S.
    Cancer; 2008 Jul 15; 113(2):286-92. PubMed ID: 18484590
    [Abstract] [Full Text] [Related]

  • 30. Indications for preoperative prostate biopsy in patients undergoing radical cystoprostatectomy for bladder cancer.
    Thomas C, Wiesner C, Melchior S, Gillitzer R, Schmidt F, Thüroff JW.
    J Urol; 2008 Nov 15; 180(5):1938-41; discussion 1941. PubMed ID: 18801501
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
    Capitanio U, Karakiewicz PI, Valiquette L, Perrotte P, Jeldres C, Briganti A, Gallina A, Suardi N, Cestari A, Guazzoni G, Salonia A, Montorsi F.
    Urology; 2009 May 15; 73(5):1087-91. PubMed ID: 19195695
    [Abstract] [Full Text] [Related]

  • 33. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial.
    Pinsky PF, Crawford ED, Kramer BS, Andriole GL, Gelmann EP, Grubb R, Greenlee R, Gohagan JK.
    BJU Int; 2007 Apr 15; 99(4):775-9. PubMed ID: 17223921
    [Abstract] [Full Text] [Related]

  • 34. Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up.
    Chaplin BJ, Wildhagen MF, Schroder FH, Kirkels WJ, Bangma CH.
    Eur Urol; 2005 Dec 15; 48(6):906-10. PubMed ID: 16126322
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Prostate cancer in patients with an abnormal digital rectal examination and serum prostate-specific antigen less than 4.0 ng/mL.
    Bozeman CB, Carver BS, Caldito G, Venable DD, Eastham JA.
    Urology; 2005 Oct 15; 66(4):803-7. PubMed ID: 16230142
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease.
    D'Amico AV, Renshaw AA, Cote K, Hurwitz M, Beard C, Loffredo M, Chen MH.
    J Clin Oncol; 2004 Sep 15; 22(18):3726-32. PubMed ID: 15365069
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.